Assessing microvascular changes in systemic sclerosis diagnosis and management

Nature Reviews Rheumatology

Volumn 6, Issue 10, 2010, Pages 578-587

  Cutolo, Maurizio ^a   Sulli, Alberto ^a   Smith, Vanessa ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; ILOPROST; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; LOSARTAN; METHOTREXATE; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTACYCLIN; RITUXIMAB; SILDENAFIL; SITAXSENTAN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

CAPILLAROSCOPY; CAPILLARY DENSITY; CLINICAL TRIAL; COLD; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FIBROSIS; HUMAN; INTERSTITIAL LUNG DISEASE; MICROANGIOPATHY; ORGAN INJURY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; SKIN ULCER; STIMULUS RESPONSE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LASER-DOPPLER FLOWMETRY; MICROSCOPIC ANGIOSCOPY; MICROVESSELS; NAILS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; THERMOGRAPHY; VASODILATOR AGENTS;

EID: 77957551169     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.104     Document Type: Review

References (75)

1. Black, C. M., Matucci-Cerinic, M. & Guillevin, L. Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) 48 (Suppl. 3), iii1-iii2 (2009).
2. Bernatsky, S. et al. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum. 61, 400-404 (2009).
3. Arias-Nuñez, M. C. et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore) 87, 272-280 (2008).
4. Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989-2003 (2009).
5. Abraham, D. J., Krieg, T., Distler, J. & Distler, O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48 (Suppl. 3), iii3-iii7 (2009)
6. Herrick, A. L. Diagnosis and management of scleroderma peripheral vascular disease. Rheum. Dis. Clin. North Am. 34, 89-114 (2008).
7. Kahaleh, M. B. Raynaud phenomenon and the vascular disease in scleroderma. Curr. Opin. Rheumatol. 16, 718-722 (2004).
8. Herrick, A. L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44, 587-596 (2005).
9. Leppert, J., Aberg, H., Ringqvist, I. & Sörensson, S. Raynaud's phenomenon in a female population: prevalence and association with other conditions. Angiology 38, 871-877 (1987).
10. Cutolo, M., Pizzorni, C. & Sulli, A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy. Arthritis Rheum. 56, 2102-2103 (2007).
11. Maricq, H. R., LeRoy, E. C. Patterns of finger capillary abnormalities in connective tissue disease by "widefield" microscopy. Arthritis Rheum. 16, 619-628 (1973).
12. Maricq, H. R., weinberger, A. B. & LeRoy, E. C. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy J. Rheumatol. 9, 289-291 (1982).
13. Cutolo, M., Grassi, W. & Matucci Cerinic, M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum. 48, 3023-3030 (2003).
14. Hettema, M. E. et al. Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. Rheumatology (Oxford) 47, 1409-1412 (2008).
15. Brülisauer, M. & Bollinger, A. Measurement of different human microvascular dimensions by combination of videomicroscopy with Na-fluorescein (NaF) and indocyanine green (ICG) in normals and patients with systemic sclerosis. Int. J. Microcirc. Clin. Exp. 10, 21-31 (1991).
16. Murray, A. K. et al. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum. 61, 1103-1111 (2009).
17. Clark, S. et al. Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon. Microvasc. Res. 66, 73-76 (2003).
18. Cutolo, M., Sulli, A., Secchi, M. E., Olivieri, M. & Pizzorni, C. The contribution of capillaroscopy to the differential diagnosis of connective autoimmune diseases. Best Pract. Res. Clin. Rheumatol. 21, 1093-1108 (2007).
19. Cutolo, M., Pizzorni, C. & Sulli, A. Nailfold video-capillaroscopy in systemic sclerosis [German]. Z. Rheumatol. 63, 457-462 (2004).
20. Cutolo, M., Pizzorni, C., Secchi, M. E. & Sulli, A. Capillaroscopy. Best Pract. Res. Clin. Rheumatol. 22, 1093-1108 (2008).
21. De Angelis, R., Cutolo, M., Salaffi, F., Pablo Restrepo, J. & Grassi, W. Quantitative and qualitative assessment of one rheumatology trainee's experience with a self-teaching programme in videocapillaroscopy. Clin. Exp. Rheumatol. 27, 651-653 (2009).
22. De Angelis, R., Grassi, W. & Cutolo, M. A growing need for capillaroscopy in rheumatology. Arthritis Rheum. 61, 405-410 (2009).
23. Carpentier, P H. & Maricq, H. R. Microvasculature in systemic sclerosis. Rheum. Dis. Clin. North Am. 16, 75-91 (1990).
24. Jayson, M. I. The micro-circulation in systemic sclerosis. Clin. Exp. Rheumatol. 2, 85-91 (1984).
25. Beyer, C., Schett, G., Gay, S., Distler, O. & Distler, J. H. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 11, 220-227 (2009).
26. Maricq, H. R. et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum. 23, 183-189 (1980).
27. Cutolo, M., Sulli, A., Pizzorni, C. & Accardo, S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J. Rheumatol. 27, 155-160 (2000).
28. Cutolo, M., Pizzorni, C. & Sulli, A. Capillaroscopy. Best Pract. Res. Clin. Rheumatol. 19, 437-452 (2005).
29. Caramaschi, P et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 46, 1566-1569 (2007).
30. Sulli, A., Secchi, M. E., Pizzorni, C. & Cutolo, M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann. Rheum. Dis. 67, 885-887 (2008).
31. Smith, V. et al. Validation of the qualitative and semiquantitative assessment of the scleroderma spectrum patterns by nailfold videocapillaroscopy: preliminary results [abstract]. Arthritis Rheum. 60 (Suppl.), S164-S165 (2009).
32. Smith, V. et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann. Rheum. Dis. 69, 1092-1096 (2010).
33. Cutolo, M. et al. Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study. J. Rheumatol. doi:10.3899/jrheum.091356.
34. Senecal, J. L., Henault, J. & Raymond, Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis. J. Rheumatol. 32, 1643-1649 (2005).
35. weiner, E. S. et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum. 34, 68-77 (1991).
36. Cutolo, M. et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 43, 719-726 (2004).
37. LeRoy, E. C. & Medsger, T. A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573-1576 (2001).
38. Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902-3912 (2008).
39. Steen, V., Denton, C. P, Pope, J. E. & Matucci-Cerinic, M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 48 (Suppl. 3), iii19-iii24 (2009).
40. Cutolo, M., Sulli, A., Secchi, M. E. & Pizzorni, C. Capillaroscopy and rheumatic diseases: state of the art [German]. Z. Rheumatol. 65, 290-296 (2006).
41. Alivernini, S. et al. Skin ulcers in systemicsclerosis: determinants of presence and predictive factors of healing. J. Am. Acad. Dermatol. 60, 426-435 (2009).
42. Sebastiani, M. et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 61, 688-694 (2009).
43. Secchi, M. E., Sulli, A., Pizzorni, C. & Cutolo, M. Nailfold capillaroscopy and blood flow laser-doppler analysis of the microvascular damage in systemic sclerosis: preliminary results [Italian]. Reumatismo 61, 34-40 (2009).
44. Caramaschi, P et al. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin. Rheumatol. 28, 807-813 (2009).
45. Coghlan, J. G. & Handler, C. Connective tissue associated pulmonary arterial hypertension. Lupus 15, 138-142 (2006).
46. Mukerjee, D. et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. 62, 1088-1093 (2003).
47. Hofstee, H. M. et al. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann. Rheum. Dis. 68, 191-195 (2009).
48. Filaci, G. et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 40, 1431-1432 (2001).
49. Filaci, G. et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 38, 992-996 (1999).
50. Smith, V. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann. Rheum. Dis. 69, 193-197 (2010).
51. Lafyatis, R. et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 60, 578-683 (2009).
52. Quillinan, N. P & Denton, C. P Disease-modifying treatment in systemic sclerosis: current status. Curr. Opin. Rheumatol. 21, 636-641 (2009).
53. van Laar, J. M. & Tyndall, A. Cellular therapy of systemic sclerosis. Curr. Rheumatol. Rep. 10, 189-199 (2008).
54. Miniati, I. et al. Autologous stem cel transplantation improves microcirculation in systemic sclerosis. Ann. Rheum. Dis. 68, 94-98 (2009).
55. Henness, S. & Wigley, F. M. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr. Opin. Rheumatol. 19, 611-618 (2007).
56. Gholam, P, Sehr, T., Enk, A. & Hartmann, M. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan). Dermatology 219, 171-173 (2009).
57. Moore, T L., Vail, A. & Herrick, A. L. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) 46, 363-364 (2007).
58. Brueckner, C. S. et al. Effect of Sildenafil on digital ulcers in systemic sclerosis-analysis from a single centre pilot study. Ann. Rheum. Dis. doi:10.1136/ard.2009.116475.
59. Hachulla, E., Launay, D. & Hatron, P Y. Iloprost for the treatment of systemic sclerosis [French]. Presse Med. 37, 831-839 (2008).
60. Caramaschi, P et al. Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin. Rheumatol. 28, 391-395 (2009).
61. Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841-1847 (2001).
62. Gliddon, A. E. et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme nhibitor quinapril. Arthritis Rheum. 56, 3837-3846 (2007).
63. Sulli, A. et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J. Rheumatol. 36, 1235-1239 (2009).
64. Dziadzio, M. et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 42, 2646-2655 (1999)
65. Herrick, A. L. Therapy: A local approach to Raynaud phenomenon. Nat Rev. Rheumatol. 5, 246-247 (2009).
66. Anderson, M. E. et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 41, 324-348 (2002).
67. Kuwana, M., Okazaki, Y. & Kaburaki, J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod. Rheumatol. 19, 530-535 (2009).
68. Akhmetshina, A. et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 60, 219-224 (2009).
69. Gabrielli, A. et al. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun. Rev. 7, 121-126 (2007).
70. Denton, C. P et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323-333 (2007).
71. Varga, J. & Pasche, B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev. Rheumatol. 5, 200-206 (2009).
72. Cutolo, M. & Matucci Cerinic, M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin. Exp. Rheumatol. 25, 663-665 (2007).
73. Hudson, M. et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin. Exp. Rheumatol. 25, 754-757 (2007).
74. Matucci-Cerinic, M. et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann. Rheum. Dis. 68, 1377-1380 (2009).
75. Herrick, A. L. & Cutolo, M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. doi:10.1002/ art.27543.